HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. [electronic resource]
Producer: 19990921Description: 677-83 p. digitalISSN:- 0269-9370
- Anti-HIV Agents -- administration & dosage
- CD4 Lymphocyte Count
- Drug Administration Schedule
- Drug Therapy, Combination
- HIV Infections -- drug therapy
- HIV Protease Inhibitors -- therapeutic use
- HIV-1 -- physiology
- Humans
- Indinavir -- therapeutic use
- Lamivudine -- therapeutic use
- Male
- Prospective Studies
- RNA, Viral -- blood
- Reverse Transcriptase Inhibitors -- therapeutic use
- Zidovudine -- therapeutic use
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.